| 股票 | 富途行业 | PE | PB | 股息率 | 分红率 | 毛利率 | ROE | 固定资产 | 负债率 | OCF/市值 | 营收增速 | 利润增速 | 近60日 | YTD | 近一年 | 距52周高 | 市值亿 ▾ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 百济神州 ONC | 生物技术 | 63.4 | 7.87 | 0.0% | 0% | 88% | 8% | 15% | 47% | 3.6% | +40% | +144% | +36% | +18% | +3% | 93% | 407 |
| 拜玛林制药 BMRN | 生物技术 | 175.1 | 2.04 | 0.0% | 0% | 78% | 6% | 14% | 20% | 6.7% | +13% | -18% | +18% | +12% | +18% | 94% | 129 |
| Corcept医疗 CORT | 生物技术 | 248.0 | 17.10 | 0.0% | 0% | 98% | 15% | 0% | 23% | 0.9% | +13% | -29% | +43% | +221% | +57% | 88% | 121 |
| Bio-Techne TECH | 生物技术 | 62.4 | 5.39 | 0.4% | 27% | 66% | 9% | 12% | 18% | 2.6% | -0% | +148% | +38% | +24% | +35% | 100% | 114 |
| Protagonist Therapeutics PTGX | 生物技术 | 141.5 | 11.20 | 0.0% | 0% | — | -20% | 1% | 8% | 1.4% | -89% | -147% | +38% | +67% | +159% | 91% | 94 |
| Telix Pharmaceuticals TLX | 生物技术 | 123.1 | 9.74 | 0.0% | 0% | 53% | -2% | 4% | 64% | 0.0% | +56% | -121% | +26% | +59% | +32% | 96% | 40 |
| Arcutis Biotherapeutics ARQT | 生物技术 | 108.6 | 13.62 | 0.0% | 0% | 90% | -9% | 1% | 56% | 1.3% | +91% | +88% | +3% | -18% | +38% | 75% | 30 |
| SL Science SLBT | 生物技术 | -261.8 | 180.00 | 0.0% | — | 35% | -95% | 3% | 19% | -0.1% | -35% | -221% | -69% | -73% | -72% | 20% | 16 |
| Apnimed APMD | 生物技术 | -34.4 | 3.69 | 0.0% | — | 83% | 0% | 1% | 612% | -6.3% | +380% | +99% | +72% | +72% | +72% | 78% | 11 |
| Pharming Group PHAR | 生物技术 | 80.2 | 2.94 | 0.0% | 0% | 88% | 1% | 6% | 45% | 4.4% | +27% | +121% | -9% | -36% | -23% | 53% | 8 |
| Vogenx VOGX | 生物技术 | -280.8 | -314.16 | 0.0% | — | — | 0% | — | 235% | -0.2% | +0% | +34% | +144% | +144% | +144% | 89% | 4 |
| Fennec Pharmaceuticals FENC | 生物技术 | -103.2 | 10.24 | 0.0% | — | 92% | -66% | — | 50% | -0.5% | -6% | -2134% | +42% | +61% | +37% | 94% | 4 |
| YD Bio YDES | 生物技术 | -30.3 | -88.50 | 0.0% | — | 28% | -445% | 0% | 121% | -2.9% | +17% | -489% | +14% | -71% | -78% | 14% | 3 |
| 健永生技 MENS | 生物技术 | -39.2 | -7.29 | 0.0% | — | — | 0% | — | 220% | -1.7% | +0% | -55% | +39% | -40% | -96% | 4% | 2 |
| vTv Therapeutics VTVT | 生物技术 | -44.5 | 1.68 | 0.0% | — | — | -70% | — | 28% | -12.7% | -100% | -37% | +10% | -17% | +78% | 76% | 1 |
| Yarrow Bioscience YARW | 生物技术 | -1.4 | 3.65 | 0.0% | — | — | 0% | — | 71% | 20.1% | +0% | +0% | +63% | +85% | +267% | 68% | 1 |
| FORTRESS BIOTECH INC 9.375% CUM RED PER PREF SER A USD25.00 FBIOP | 生物技术 | 0.0 | 0.39 | 0.0% | — | 67% | -5% | 8% | 66% | 196.0% | +10% | +73% | -7% | +98% | +105% | 88% | 1 |
| Impact BioMedical IBO | 生物技术 | 77.1 | 5.40 | 0.0% | 0% | -1225% | -141% | 0% | 11% | -0.9% | +0% | +52% | -5% | +7% | -12% | 65% | 1 |
| Polyrizon PLRZ | 生物技术 | -2.3 | 1.11 | 0.0% | — | — | -25% | — | 2% | -19.3% | +0% | -116% | +2% | +32% | +88% | 62% | 0 |
| Immuron IMRN | 生物技术 | -4.8 | 1.83 | 0.0% | — | 64% | -40% | 0% | 15% | 0.0% | +11% | +23% | +54% | +136% | -4% | 75% | 0 |
| Moolec Science MLEC | 生物技术 | -0.1 | 1.56 | 0.0% | — | 38% | 0% | 4% | 140% | 40.7% | -28% | -508% | -4% | +82% | -59% | 30% | 0 |
| Xenetic Biosciences XBIO | 生物技术 | -4.1 | 1.80 | 0.0% | — | — | -40% | — | 12% | -21.1% | +19% | +32% | +56% | +115% | +53% | 34% | 0 |
| Pulmatrix PULM | 生物技术 | -1.3 | 3.19 | 0.0% | — | — | -81% | — | 8% | -77.0% | -100% | +46% | +2% | -38% | -71% | 25% | 0 |
| 知临集团 NIKI | 生物技术 | -2.1 | 0.22 | 0.0% | — | — | -6% | — | 26% | -51.0% | +0% | +67% | -31% | -42% | -64% | 24% | 0 |
| Silo Pharma SILO | 生物技术 | -0.6 | 0.86 | 0.0% | — | 39% | -75% | — | 17% | -79.4% | +0% | +4% | -62% | -53% | -73% | 16% | 0 |
| XORTX Therapeutics XRTX | 生物技术 | -0.9 | 0.76 | 0.0% | — | — | -98% | — | 22% | -121.5% | +0% | +20% | +1% | -18% | -44% | 33% | 0 |
| Alaunos Therapeutics TCRT | 生物技术 | -0.9 | 6.34 | 0.0% | — | — | -198% | 1% | 27% | -65.9% | -50% | +11% | -17% | -50% | -26% | 36% | 0 |
| Mustang Bio MBIO | 生物技术 | -1.3 | 0.55 | 0.0% | — | — | -68% | — | 46% | -109.7% | +0% | +88% | -26% | -45% | -60% | 29% | 0 |
| Bone Biologics BBLG | 生物技术 | -2.0 | 0.40 | 0.0% | — | — | -70% | — | 7% | -167.8% | +0% | +24% | -54% | -61% | -74% | 20% | 0 |
点表头排序。市值单位亿美元;财务为最近年报(futu 筛选器);分红率 = 股息率 × PE;OCF/市值 = 经营现金流 ÷ 市值(无 FCF);距52周高 = 现价 / 52 周最高。